INTELGENXHome  >  Investors  >  Press Releases
INTELGENXHome  >  Investors  >  Press Releases
2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
IntelGenx Closes $3.5 Million Public Offering December 16, 2013
IntelGenx Announces Public Offering of $3,500,000 of Common Stock December 12, 2013
IntelGenx Reports Q3, 2013 Results and Corporate Development Highlights November 8, 2013
IntelGenx Corp. Receives Buprenorphine/Naloxone Sublingual Film Product Patent Infringement Complaint August 26, 2013
IntelGenx Receives Paragraph IV Certification Letter on Submission of ANDA for Forfivo XL® August 22, 2013
IntelGenx Reports Q2, 2013 Results and Corporate Development Highlights August 8, 2013
IntelGenx Announces Submission of ANDA for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction July 22, 2013
IntelGenx Announces FDA Acceptance of New Drug Application for Anti-Migraine VersaFilm(TM) Oral Film Product June 18, 2013
IntelGenx Reports Q1, 2013 Results and Provides Operational Update May 14, 2013
IntelGenx Secures Leadership Succession April 24, 2013
IntelGenx submits New Drug Application for Anti-Migraine VersaFilm(TM) March 27, 2013
IntelGenx Reports 2012 Annual Results and Provides Operational Update March 18, 2013
IntelGenx to Present at Roth Capital Partners 25th Annual Growth Stock Conference March 18, 2013

Shareholder Tools

Financial Reports E-mail Alerts RSS News Feeds

About us

Product

R&D Services

Manufacturing Services

Partnering

Investors

More Links

© Copyright 2017. IntelGenx Corp. All Rights Reserved.
Powered By Q4 Inc. 5.14.0.5